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platform using monogenic diabetes as a
study-model
Rui Gao1, Yanxia Liu1, Anette Prior Gjesing2, Mette Hollensted2, Xianzi Wan1, Shuwen He3, Oluf Pedersen2, Xin Yi1*,
Jun Wang1,2,6* and Torben Hansen2,4,5*Abstract
Background: Monogenic diabetes is a genetic disease often caused by mutations in genes involved in beta-cell
function. Correct sub-categorization of the disease is a prerequisite for appropriate treatment and genetic
counseling. Target-region capture sequencing is a combination of genomic region enrichment and next generation
sequencing which might be used as an efficient way to diagnose various genetic disorders. We aimed to develop
a target-region capture sequencing platform to screen 117 selected candidate genes involved in metabolism for
mutations and to evaluate its performance using monogenic diabetes as a study-model.
Results: The performance of the assay was evaluated in 70 patients carrying known disease causing mutations
previously identified in HNF4A, GCK, HNF1A, HNF1B, INS, or KCNJ11. Target regions with a less than 20-fold sequencing
depth were either introns or UTRs. When only considering translated regions, the coverage was 100% with a 50-fold
minimum depth. Among the 70 analyzed samples, 63 small size single nucleotide polymorphisms and indels as well
as 7 large deletions and duplications were identified as being the pathogenic variants. The mutations identified by
the present technique were identical with those previously identified through Sanger sequencing and Multiplex
Ligation-dependent Probe Amplification.
Conclusions: We hereby demonstrated that the established platform as an accurate and high-throughput gene
testing method which might be useful in the clinical diagnosis of monogenic diabetes.Background
Since 1992, several genetic subtypes of monogenetic dia-
betes have been described in which gene mutations result
in diabetes, primarily by causing beta-cell dysfunction [1].
Thus, patients previously categorized clinically as having
maturity-onset diabetes of the young (MODY), permanent
neonatal diabetes mellitus (NDM), or transient NDM, can
now be classified by genetic sub grouping. Identification
of the genetic subgroups is a prerequisite for appropriate
treatment, genetic counseling, and prognostic information.
MODY, defined as dominantly inherited, young-onset
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reproduction in any medium, provided the orof age), non-autoimmune and non-insulin dependent
diabetes (no insulin treatment needed three or more
years after diabetes diagnosis or measurable circulating
C-peptide) [1,2], is the most common form of monogen-
etic diabetes. Molecular genetic findings have shown that
MODY is very heterogeneous. To date, the MODY
phenotype has been reported to be linked with muta-
tions within 13 different genes: HNF4A (MODY1), GCK
(MODY2), HNF1A (MODY3), PDX1 (MODY4), HNF1B
(MODY5), NEUROD1 (MODY6), KLF11 (MODY7), CEL
(MODY8), PAX4 (MODY9), INS (MODY10), BLK
(MODY11) and very recently ABCC8 (MODY12) and
KCNJ11 (MODY13) [3-5]. Approximately 70-80% of
clinically diagnosed MODY patients carry mutations
in one of these 13 genes, however, the remaining 20-30%
are likely to carry disease causing mutations in yet uniden-
tified genes [1,6-8]. Thus, the term MODY encompasses a
group of clinically and genetically heterogeneous forms of. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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resistance which at a molecular level is defined by muta-
tions in various genes [2,5].
NDM, a form of monogenic diabetes which is usually
diagnosed within the first six months of life, has a rare
incidence of one in 100,000 to 400,000 live births. Clin-
ically, NDM can be divided into two subtypes: transient
neonatal diabetes mellitus (TNDM) and permanent neo-
natal diabetes mellitus (PNDM). The most frequent cause
of PNDM is due to mutations in KCNJ11 or ABCC8
which encode a subunit and a modulator of the ATP-
sensitive potassium (KATP) channels in the pancreatic
beta-cell, respectively [9]. Patients with PNDM due to
KCNJ11 or ABCC8 mutations may be treated with oral
sulfonylurea instead of insulin [1].
The monogenic subset of the diabetic population is
often mis-classified as type 1 diabetes (T1D) or type 2
diabetes (T2D) and thus is not offered optimal treatment
regimens [10]. In Europe and USA, approximately 2-5%
of T2D and 10% of familial T1D have previously been
estimated to be misdiagnosed MODY cases [11,12], how-
ever, the exact incidence and prevalence of monogenic
diabetes is not known. According to recent estimates,
approximately 92 million Chinese are recognized dia-
betes patients, making China one of the world’s leading
countries with regards to diabetes prevalence [13]. In the
latest report, 27.7 million Chinese children and 334 million
Chinese adults are estimated to be pre-diabetic or diabetic
[14]. With this high diabetes prevalence and the known
high prevalence of specific MODY forms in young onset
diabetic patients in China [15,16], the prevalence of mono-
genic diabetes cases in China is likely to be accordingly
high, and the importance of clinical differentiation should
thus not be ignored. A high-throughput method with high
accuracy to diagnose monogenic forms of diabetes is
needed not only for a scientific purpose but also for
medical application. Due to its high accuracy, Sanger se-
quencing is still the gold standard in terms of gene variant
detection. However, when it comes to heterogeneous
disorders, the method requires accurate clinical assess-
ments and gene selection. If the “wrong gene” is tested, a
(false) negative result is obtained and the testing procedure
has to be repeated. In this case, the method is time con-
suming and expensive.
Here, we present the use of a gene testing panel (117
genes) based on a target region capture system coupled
with next-generation sequencing (NGS) technology. The
performance of the capture probe was tested by use of
in-house YanHuang (YH) DNA [17]. The assay per-
formance was validated by investigating six of the
known monogenic diabetes genes (HNF4A, GCK, HNF1A,
HNF1B, INS and KCNJ11) in 70 Danish patients carrying
previously identified causative variants. All 70 causative
variants were correctly identified. We therefore believethe established platform to be a high-throughput gene
testing method which may be applied in clinical diagnosis
of monogenic diabetes.
Methods
Samples
As a means to test the use of the platform, six YH
samples were contributed from the Clinical Laboratory
Center at Beijing Genomic Institute (BGI) [17], Shenzhen.
For the validation of the method in relation to detection
of known diabetes causing mutations, a total of 70 sam-
ples from unrelated Danish MODY and NDM probands
collected at Steno Diabetes Center, Gentofte, Denmark,
were examined. Prior to the participation in the study, in-
formed consent was obtained from all subjects. The study
was approved by the Ethical Committee of Copenhagen
and was in accordance with the principles of the
Declaration of Helsinki II.
Target region array design
A customized oligonucletide probe was designed to
capture whole genome regions (including exons, introns,
and untranslated regions (UTRs)) of 117 genes for mono-
genic diabetes [3-5] and selected candidate genes referred
to type 2 diabetes mellitus, metabolism of glucose and oral
hypoglycemic agents, and obesity [2,18,19] (Additional
file 1: Table S1). Hence, the total size of probe set
was 4962226 bp. The probes (GenCap™ Enrichment,
MyGenostics, USA) were approximately 60 bp in length
and with a 5-10 bp overlap in restricted regions.
DNA extraction, target region capture and next-
generation sequencing
Methods for DNA extraction, target region capture, and
NGS have previously been extensively described [20] and
a brief experimental workflow is included in Additional
file 1: Figure S1. In brief, genomic DNA was extracted
from peripheral blood lymphocytes by standard pro-
cedures using QIAamp DNA Bloodmini kits (Qiagen,
Germany). Next, 1 ug genomic DNA was fragmented
by Covaris sonicator (Covaris S2, USA) to sizes of
150-300 bp and then purified. The blunt ends of the
purified DNA fragments were then repaired, and A-tailing
was added. The fragments were ligated overnight using
standard Illumina paired-end (PE) adapter. The ligated
products were then amplified through 4-cycle polymerase
chain reactions (PCRs) using PE primers containing 8 bp
index tags. The purified PCR products containing 3 ug
DNA were hybridized to the GenCap™ probe (in solution)
at 65°C for 22 hours using a PCR machine. The products
were bound to a rotator for 1 hour at room tempe-
rature using Dynal Myone Streptavidin C1 magnetic
beads (Invitrogen, USA), which had been activated
beforehand, and the products were then washed with
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braries were amplified using 15-cycle PCRs, purified, and
subsequently eluted in a 30 ul volume and subjected to
Agilent 2100 Bioanalyzer and quantitative PCR to estimate
the magnitude of enrichment. The final captured DNA
libraries were sequenced using the Illumina HiSeq2000
Analyzers as PE 90 bp reads (following the manufacturer’s
standard cluster generation and sequencing protocols),
providing an average coverage depth for each sample of at
least 100-fold.
Data filtering and analysis
Image analysis, error estimation, and base calling were
performed using the Illumina pipeline (version 1.3.4)
with default parameters. Indexed primers were used to
identify the different samples in the primary data. All
unqualified reads (defined as reads either polluted by
adapter, containing more than 10% nucleotides out of
read length, having an average quality of less than 10, or
having 50% bases with a quality value less than 5) were
removed using a local dynamic programming algorithm.
The remaining reads were aligned to the reference hu-
man genome (UCSC hg19) using Burrows-Wheeler
Alignment Tool (BWA-0.5.9). Next, SNPs and indels
were identified using SOAPsnp software 2.0 and SAM-
tools v1.4 while using the recommended parameters
[21,22].
FNFP assessment
The accuracy and precision of the targeted region cap-
ture sequencing were assessed by comparing SNPs iden-
tified in one of the 6 YH samples with those reported in
the online YH database (http://yh.genomics.org.cn/). The
remaining 5 YH samples were used as inter-control
samples.
According to the YH database reference, an in-house
pipeline was used to estimate the true positive (TP) ratio,
true negative (TN) ratio, false positive (FP) ratio, and false
negative (FN) ratio of all SNPs [23]. The accuracy and pre-
cision was calculated by (TP + TN)/(TP + FN+TN + FP)
and TP/(TP + FN), respectively. In this calculation, only
high quality SNPs fulfilling the following criteria were in-
cluded: 1) SOAPsnp score ≥ 20; 2) Depth ≥ 20; 3) Percent-
age of reads supporting variation ≥ 28% [24].
Functional annotation of genetic variants
The variants were functionally annotated using an in-
house pipeline as well as the reported frequencies available
from public databases (dbSNP 135, HapMap database,
1000 genome variants database, and a local control data-
base) and categorized into either missense, nonsense,
splice-site, insertion, deletion, synonymous or noncoding
mutations. For all variants, the results were filtered using
a quality value of single base sequencing ≥ 20. The variantswere filtered to potential mutation candidates through: 1).
Functional variants (insertion/deletion: in CDS and
splicing region, SNP: nonsense, splice site and missense)
and 2). Variants with an allele frequency below 0.01 in
either of the public databases mentioned above. To valid-
ate the pre-screened samples, variants were initially fil-
tered by six known disease-causing genes (HNF4A, GCK,
HNF1A, HNF1B, INS and KCNJ11).
The identification of known pathogenic variants was
based on mutations previously reported to cause MODY
in the literature, in Locus Specific Mutation Databases
(LOVD, http://grenada.lumc.nl/LSDB_list/lsdbs) or pre-
viously identified to segregate with diabetes in Danish
MODY families. Novel variants considered to be patho-
genic were either: 1) stop/frameshift variants; 2) missense
mutations positioned in the amino acid conservative re-
gion across species; 3) splice-site variations fulfilling
the GT-AT rules; or 4) predicted to be possibly dam-
aging or disease-causing by more than two of the bio-
informatic programs (SIFT, Sorting Intolerant From
Tolerant, http://sift.bii.a-star.edu.sg/; PolyPhen-2, http://
genetics.bwh.harvard.edu/pph2/; Mutation Taster, http://
www.mutationtaster.org/; BDGP, Berkeley Drosophila
Genome Project, http://www.fruitfly.org/seq_tools/splice.
html) [25].
Large deletions/duplications analysis
The depths of each region of a gene in different samples
within the same sequencing lane are significantly corre-
lated (r > 0.7), and the depth of each capture region was
therefore used to calculate a z-score according to the
following equation:
z ¼
X−μ0
σ0=
ﬃﬃﬃ
n
p ¼ meanDepth rate‐region−meanDepth rate‐total
Standard Deviation
Formula.1 z-score is calculated for large deletions/du-
plications analysis. Mean Depth rate-region=
MeanDeptheach region
MeanDeptheach sample
;
Mean Depth rate-total=
∑Depthrateother region
N , other region
means other regions of the samples operated in the
same run.
The large deletions and duplications were identified
using a predefined cut-off point (±3) of derived z-score
of each captured gene region. We used the cut-off value
of 3 for absolute z-score, as it represents the 99.9th per-
centile of the normal samples set for one tailed region.
Any region with a z-score above 3 was defined as either
a deletion (<-3) or a duplication (> 3).
Results
General performance of the overall sequencing
In total, we collected 76 samples to assess the method of
target region capture combined with high-throughput
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supplementary information (Additional file 1: Figure S1)
and the average performance of the method is provided
in Table 1. For each sample, we obtained an average of
4409.95 Mb raw data of which 2046.69 Mb was mapped
to the target region after alignment using BWA. The
specificity of the probe was 53.72%, the overall coverage
of the target region was 99.37% and 96.95% for a mini-
mum depth of 1X and 20X, respectively, and the average
sequencing depth was 412-fold (Table 1). For the 200 bp
flanking target regions, the coverage was 94.45%, and
the average depth was 240-fold (Table 1). The mean
depth and the coverage of the target region for each
screened sample are provided in Figure 1.
Using SOAPsnp and SAMtools for variant calling
[21,22], we obtained a total of 15875 variants in the 117
genes on average pr. sample, including 13808 SNPs and
2067 indels. All variants were annotated as either heterozy-
gous (het) or homozygous (hom) using the bioinformatics
software (hom-0.0005, het-0.0010) [21]. Overall, 96.83%
and 1.12% of SNPs were located in the introns and exons,
respectively (Table 2), and the percentage of heterozygotic
and homozygotic SNPs was 70.94% and 29.06%, respect-
ively (Table 2). In each screened sample, an average of 70
missense, 18 splice site, 1 nonsense, and 66 synonymous
mutations were identified.
With regards to the indels, 97.28% and 0.2% were
located in introns and exons, respectively, and the per-
centage of heterozygotic and homozygotic indels was
93.27% and 6.73%, respectively (Table 3). Furthermore,
on average, each sample had a total of 1226 deletions
and 841 insertions in the all gene region, 3 deletions and 1
insertion positioned within a coding region, and 1 indel
positioned in a splice site region.Table 1 Statistics of the performance
Target region capture statistics Value
Target region (bp): 4962226
Raw data yield (Mb) 4409.95
Data mapped to target region (Mb): 2046.69
Reads mapped to genome: 48535673.13
Reads unique mapped to genome: 46489667.46
Reads mapped to target region: 25879158.93
Mean depth of target region: 412.45
Coverage of target region > =1X (%): 99.37
Coverage of target region > =20X (%): 96.95
Average read length (bp): 89.11
Capture specificity (%): 53.72
Mean depth of flanking region: 240.00
Coverage of 200 bp flanking region (%): 94.45
The target region capture performance is presented in average value of all
76 the sequenced samples.Accuracy and precision of target region captured
sequencing
To assess the accuracy of the method, we used the YH
DNA as a control sample, as genome information of this
sample was readily available [17]. In this sample, the
relative TP, TN, FN and FP ratio for all SNPs were
90.96%, 99.99%, 9.04%, and 0.006%, respectively. The
precision of sequencing was 95.43%, and the accuracy
was 99.98% (Table 4).
Identified variants in monogenic diabetes samples
To validate whether the method can accurately detect
causative variants in patients with known disease causing
mutations in HNF4A, GCK, HNF1A, HNF1B, INS, or
KCNJ11, we applied the method to 70 samples from Danish
patients.
In regions with a more than 20-fold minimum depth,
the coverage was 97.87%. Regions with a less than 20-fold
depth were either introns or UTRs. Moreover, when only
considering translated regions, the coverage was 100%
with a 50-fold minimum depth. Thus, by selecting only
genes of relevance for the individuals phenotype combined
with data filtering, the number of potential pathogenic
variants (indel, missense, nonsense, and splice-site) [5,23]
in each sample could be narrowed down to 3-10 variants.
These variants were arbitrarily defined to be either pa-
thogenic, suspected pathogenic, polymorphism or of
unknown significance. Mutations previously reported in
MODY patients, or leading to loss of function due to the
introduction of a stop codon or a frameshift, were termed
pathogenic (n = 51). For novel mutations, functional pre-
diction was performed with the use of bioinformatics
tools. If novel mutations were located in important func-
tional regions and/or conservative regions, they were
defined as suspected pathogenic (n = 12). Polymorphisms,
i.e. variants detected in both diabetes patients and controls,
were predicted to be benign, and the remaining variants
were defined as being of unknown significance. Hence, in
70 positive samples, we identified 63 pathogenic variants,
including 15 indels, 36 missense, 5 nonsense, and 7 splice-
site variants (Figure 2 and Additional file 1: Table S2). In
the remaining 7 samples, we identified large deletions
or duplications in exons (Additional file 1: Table S2,
Additional file 1: Figure S3). Among the 70 samples, the
percentage of GCK-mutated samples was 37%, HNF1A was
40%, HNF4A was 13%, HNF1B was 3%, INS was 3%, and
KCNJ11 was 4% (Additional file 1: Table S2). In addition, a
series of polymorphisms and variants of unknown signifi-
cance located within these genes was also identified.
The clinical characteristics of Danish patients of
monogenic diabetes mellitus
The clinical characteristics were collected at Steno Diabetes
Center, Denmark and included the pathogenic gene, sex,
Sample Number
Figure 1 Depth and coverage of all pre-screened samples. For each screened sample (X-axis), the sequencing depth and the coverage of at
least 1-fold depth are depicted as square (■) and diamond (◆), respectively. The Y-axis are Mean Depth (left) and coverage (right) respectively.
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HbA1c and treatment of every patient (Table 5). All 70
patients were diagnosed with diabetes mellitus at a young
age, except one patient who was diagnosed with hyperin-
sulinemic hypoglycemia. Furthermore, all patients had a
normal BMI and slightly elevated levels of HbA1c, and
these clinical characteristics are all corresponding to the
known features of monogenic diabetes. With the use of
target region capture NGS, 100% of pathogenic variants
previously identified by Sanger sequencing and MLPA
were detected in a study sample of 70 Danish patients
with known monogenic forms of disease. Therefore, the
targeted NGS approach was demonstrated to be an accur-
ate and reliable method to detect variants of monogenic
diabetes or hyperinsulinemic hypoglycemia.
Discussion
In the present study, target region enrichment combined
with NGS technology proved to be a useful tool for the
identification of genetic variants involved in monogenicTable 2 Statistics of the SNP count
SNP
classification
n Ratio
(%)
SNP
classification
n Ratio
(%)
Missense 70.01 0.51 Hom 4012.28 29.06
Splice-site 17.97 0.13 Het 9795.97 70.94
Nonsense 0.79 0.01
Synonymous 66.28 0.48
5′UTRs 23.45 0.17
3′UTRs 187.75 1.36
Intron 13370.00 96.83
Intergenic 72.00 0.52
Read-through 0.00 0.00
Total number of SNPs 13808.25
The average number of single nucleotide polymorphisms (in different categories)
identified by sequencing 117 genes in 76 samples.diabetes. The hybridizing procedure to enrich target region
is easy to use, and the duration of the total process is
approximately 30 hours which is considerably less than
performing directional sequencing of each gene. Combined
with the applied sample pooling strategy, the target region
capture procedure proved to be very effective. With the
use of this method, 117 genes potentially implicated in
metabolic disorders could be analyzed in one run. Each
sample generated an average of 2005.13 Mb data mapped
to the target region. Though the capture specificity of the
applied chip is relatively low (53.72% compared to ~70%
on other commercial chips, e.g. Nimblegen EZ Choice),
the compatible performance in capture coverage (reducing
the FN rate) as well as the lower cost (20% more sequen-
cing cost is also considered) makes the present capture
chip a good choice for target-region capture sequencing.
For the entire testing panel, the coverage of the 117 genes
was 99.38%, and the coverage was only slightly diminished
(96.95%) at 20-fold minimum depth.
To assess the accuracy of the method, in-house YH
DNA was initially tested. We found that after filtering of
the low quality variants, the accuracy was 95%, and both
the FP and FN ratio reached the lowest value. Neverthe-
less, comparison with the reference data revealed that
the FN ratio was still quite high (9.04%). The relatively
high FN ratio may be due to errors in the YH reference
sequence; such false positives in the reference sequence
will cause an inflated FN rate in the examined sequence.
This is supported by the fact that an FN ratio of 5-10%
has also been observed in other previous studies using
the YH reference sequence [23].
By applying this method, a total of 70 pre-screened
samples were tested, and in 100% of the samples, we
were able to detect known mutations. With the use of
this method, small variants (both SNPs and indels) as
well as larger deletions and duplications could be iden-
tified in one analysis. In order to apply the method in
Table 3 Statistics of the indel count
Indel classification n Ratio (%) Indel classification n Ratio (%) Indel classification n Ratio (%)
Del-coding 2.93 0.14 Het InDels 1927.41 93.27 Total deletion 1225.63 59.31
Ins-coding 1.26 0.06 Hom InDels 139.14 6.73 Total insertion 840.92 40.69
Splice-site 0.80 0.04
Intron 2030.18 97.28
5′UTRs 3.00 0.14
3′UTRs 47.00 2.25
Promo 1.68 0.08
Intergenic 0.00 0.00
Total number of indels 2066.55
The average number of small deletions and insertions (< 10 bp) identified by sequencing 117 genes in 76 samples.
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mented. Firstly, the gene panel could be re-designed to
include only translated regions of phenotype specific
genes (known causative genes, candidate genes for
MODYX, other disease functional related genes), plus
regulatory regions with reported causative mutations, for
example the P2 promoter of HNF4A [26]. Secondly, any
low coverage regions should be supplemented by Sanger
sequencing methods in order to improve the mutation
detection rate. Thirdly, our assay at its current form has
a turnaround time of seven weeks, which is relatively
long for routine clinical testing and reporting. Therefore,
transferring the sequencing procedure from Hiseq to
Miseq or Proton might shorten turnaround time while
maintaining the high accuracy and throughput. Last but
not least, clinical variation interpretation can be a great
challenge. Thus, we suggest a “phenotype-specific candi-
date-genes panel” approach i.e. only genes of relevance to
the individuals’ phenotype are analysed in order to reduce
the number of variants identified to facilitate theTable 4 The accuracy and precision assessment
Filtered conditions SOAPsnp score ≥ 20;
Depth ≥ 20;
Percentage of reads
supporting ≥ 28%
Target covered: 4944470 bp
Total number of SNPs: 9572
Total number of target SNPs: 6127
YH target in dbSNP: 6463
True positive (TP ratio): 5847 (90.96%)
True negative (TN ratio): 4937762 (99.99%)
False negative (FN ratio): 581 (9.04%)
False positive (FP ratio): 280 (0.006%)
Accuracy (%)((TP + TN)/(TP + FN + TN + FP)): 99.98
Precision (%)(TP/(TP + FN)): 95.43
The assessment is calculated based on qualified SNPs filtered by SOAPsnp
score, depth, and supporting reads ratio.interpretation of the pathogenicity of the variants [27]. A
similar approach was recently published targeting the cod-
ing regions of 29 genes in which mutations have been re-
ported to cause neonatal diabetes, MODY, maternally
inherited diabetes and deafness (MIDD) or familial partial
lipodystrophy (FPLD) [28]. However, as the present plat-
form includes a much larger number of genes, includes
non-coding region, and has the ability to identify larger
structural variations, we believe that the present platform
has a greater usability.
Conclusions
We have established a straight-forward target region se-
quencing method for examining a large number of
genes. The method was successfully evaluated using
monogenic diabetes as a study-model. The turnaround
time was seven weeks, and the coverage of the target
gene coding region reached 100%. The method can be
used to detect small size mutations and larger deletions
and/or duplications in the same run. In terms of the 70Figure 2 The distribution of pathogenic (suspected pathogenic)
variants of disease-causing genes among 70 pre-screened
samples. The mutation type (large exon deletion/duplication, splice,
nonsense, missense, small indel) are present by gradually changing
color in blue.
Table 5 Phenotype information
Gene n Sex (m/f) Age at examination
(years) [NA]
Age at diagnosis
(years) [NA]
Height (cm) [NA] Weight (kg) [NA] BMI (kg/m2) [NA] HbA1c (%) Treatment
(ins/ins + OHA/OHA/diet) [NA]
GCK 26 10/16 23.84 (1.4-73) [1] 16.26 (1.4-35) [3] 155.55 (80-176) [5] 55.53 (12-95.5) [4] 21.63 (13.46-37.59) [4] 6.56 (5.9-8.1) [3] 1/1/5/17 [2]
HNF1A 28 14/14 35.14 (8-60) [0] 23.24 (8-49) [3] 171.45 (155-188.5) [8] 71.48 (50.8-106.6) [8] 24.26 (18.82-37.77) [8] 7.42 (5.5-9.4) [8] 7/1/10/5 [5]
HNF1B 2 0/2 29.5 (26-33) [0] 29 (26-32) [0] 167 (162-172) [0] 58.25 (55.4-61.1) [0] 21.00 (18.73-23.28) [0] 6.05 (5.6-6.5) [0] 1/0/1/0 [0]
HNF4A 9 1/8 22.33 (4-35) [0] 15.67 (4-34) [0] 157.19 (96.5-183) [1] 57.34 (15.4-81.3) [1] 22.17 (16.54-25.59) [1] 7.09 (5.5-8.4) [1] 3/1/0/5 [0]
INS 2 2/0 39.5 (35-44) [0] 10.6 (0.2-21) [0] 171.5 (169-174) [0] 72.2 (71-73.4) [0] 24.55 (24.24-24.86) [0] 6.8 (5.9-7.7) [0] 1/0/1/0 [0]
KCNJ11 3 2/1 6.83 (3.5-13) [0] 0.33 (0.2-0.5) [0] 131.5 (108-155) [1] 29.9 (20.8-39) [1] 17.03 (16.23-17.83) [1] 7.37 (6.4-8.1) [0] 3/0/0/0 [0]
Total 70 29/41 28.11 (1.4-73) [1] 18.38 (0.2-49) [6] 161.69 (80-188.5) [15] 61.26 (12-106.6) [14] 22.58 (13.46-37.77) [15] 6.96 (5.5-9.4) [12] 16/3/17/27 [7]
The clinical characteristics of 70 Danish patients with known mutations in GCK, HNF1A, HNF1B, HN4A, INS or KCNJ11.
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http://www.biomedcentral.com/1471-2156/15/13pre-screened samples, we correctly identified all the
causative variants. We believe our method could be a
useful tool in large-scale monogenic diabetes gene
testing.
Additional file
Additional file 1: Table S1. The examined genes on designed capture
panel. Table S2. Overview of the pathogenic variants of six monogenic
diabetes mellitus’ casual genes. Figure S1. Workflow of experimental
procedure before sequencing. Figure S2. Bioinformatics analysis pipeline.
Figure S3. Detection of 7 large deletions or duplications in Danish
patients with known monogenic diabetes. YH4 is shown as control.
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